What class of medication is Effexor (venlafaxine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Effexor Drug Classification

Effexor (venlafaxine) is a serotonin-norepinephrine reuptake inhibitor (SNRI), a class of antidepressant that inhibits the presynaptic reuptake of both serotonin and norepinephrine. 1, 2

Mechanism of Action

  • Venlafaxine blocks the reuptake of both serotonin (5-HT) and norepinephrine with a 30-fold selectivity for serotonin over norepinephrine. 3

  • At lower therapeutic doses, venlafaxine primarily inhibits serotonin reuptake, while at higher therapeutic doses (typically above 150 mg/day), it inhibits both serotonin and norepinephrine reuptake. 4

  • This dual mechanism distinguishes venlafaxine from selective serotonin reuptake inhibitors (SSRIs), which only affect serotonin reuptake. 1

Key Distinguishing Features from Other Antidepressants

  • Unlike tricyclic antidepressants (TCAs), venlafaxine lacks significant activity at muscarinic cholinergic, H1 histaminergic, and alpha-1 adrenergic receptors, resulting in a side-effect profile more similar to SSRIs. 5

  • The SNRI classification is clinically important because it differentiates venlafaxine from SSRIs in treatment algorithms for conditions like social anxiety disorder and generalized anxiety disorder. 1

  • Venlafaxine shares its SNRI classification with duloxetine and milnacipran, though these medications should never be combined due to the significant risk of serotonin syndrome. 2

Clinical Implications of SNRI Classification

  • The norepinephrine reuptake inhibition component contributes to efficacy in chronic pain conditions, particularly neuropathic pain, which distinguishes SNRIs from SSRIs that are generally ineffective for chronic pain. 3

  • The dual mechanism requires monitoring for noradrenergically-mediated side effects including dose-dependent blood pressure elevation (particularly at doses >225 mg/day), dry mouth, and constipation. 2, 6, 3

  • Blood pressure and pulse must be measured regularly when prescribing venlafaxine, especially at higher doses, due to its norepinephrine effects. 6

References

Guideline

SNRI Classification and Clinical Implications

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Contraindications and Risks of Combining Duloxetine and Venlafaxine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Neuropharmacology of venlafaxine.

Depression and anxiety, 2000

Research

Venlafaxine:a novel antidepressant compound.

Expert opinion on investigational drugs, 1997

Guideline

Utilisation de la Venlafaxine pour l'Anxiété et la Douleur Chronique

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.